Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,253
  • Shares Outstanding, K 32,203
  • Annual Sales, $ 63,260 K
  • Annual Income, $ 6,820 K
  • EBIT $ -66 M
  • EBITDA $ -58 M
  • 60-Month Beta 1.44
  • Price/Sales 1.23
  • Price/Cash Flow N/A
  • Price/Book 1.21

Options Overview Details

View History
  • Implied Volatility 272.93% (+170.90%)
  • Historical Volatility 59.97%
  • IV Percentile 86%
  • IV Rank 22.12%
  • IV High 1,000.47% on 11/10/25
  • IV Low 66.25% on 11/20/25
  • Expected Move (DTE 1) 0.40 (17.07%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 590
  • Volume Avg (30-Day) 327
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 18,511
  • Open Int (30-Day) 17,495
  • Expected Range 1.94 to 2.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.48
  • Growth Rate Est. (year over year) +208,225.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.20 +6.59%
on 04/07/26
3.24 -27.73%
on 03/18/26
-0.74 (-24.11%)
since 03/16/26
3-Month
2.20 +6.59%
on 04/07/26
4.22 -44.43%
on 02/23/26
-1.38 (-36.96%)
since 01/16/26
52-Week
1.45 +61.72%
on 04/22/25
4.53 -48.23%
on 01/09/26
+0.85 (+56.33%)
since 04/16/25

Most Recent Stories

More News
Fortress Biotech: Q4 Earnings Snapshot

Fortress Biotech: Q4 Earnings Snapshot

FBIO : 2.34 (-3.70%)
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205...

FBIO : 2.34 (-3.70%)
FBIOP : 13.00 (-1.59%)
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing...

FBIO : 2.34 (-3.70%)
FBIOP : 13.00 (-1.59%)
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™  generated net revenues of $14.7 million during the full-year period after its launch in early April 2025...

FBIO : 2.34 (-3.70%)
DERM : 5.15 (-2.83%)
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused...

FBIO : 2.34 (-3.70%)
DERM : 5.15 (-2.83%)
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...

FBIO : 2.34 (-3.70%)
FBIOP : 13.00 (-1.59%)
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...

FBIO : 2.34 (-3.70%)
FBIOP : 13.00 (-1.59%)
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE...

FBIO : 2.34 (-3.70%)
ATXI : 0.6400 (+25.49%)
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million...

FBIO : 2.34 (-3.70%)
FBIOP : 13.00 (-1.59%)
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the...

FBIO : 2.34 (-3.70%)
FBIOP : 13.00 (-1.59%)

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 2.58
2nd Resistance Point 2.54
1st Resistance Point 2.48
Last Price 2.34
1st Support Level 2.38
2nd Support Level 2.34
3rd Support Level 2.28

See More

52-Week High 4.53
Fibonacci 61.8% 3.35
Fibonacci 50% 2.99
Fibonacci 38.2% 2.63
Last Price 2.34
52-Week Low 1.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.